Willow Review: A $199 NAD+ Price With No Ladder Under It

Willow sells a 50 mg NAD+ injection for $199 a month, and that is the real month-to-month rate: no three-, six- or twelve-month prepay rung anywhere in the sign-up, no discounted first month, cancel whenever you like. Most advertised prices in this category are a prepay figure wearing a per-month suffix, so a number with nothing hiding under it is worth pointing at.

The caveat has to come almost as early. Willow sells no sermorelin and no growth-hormone peptide of any kind. If you came here from the peptide side of this site, read the next section first.

What Willow does not sell

Willow's catalog is five products: an NAD+ injection, and compounded semaglutide and tirzepatide each in an injectable and a sublingual form. That is the whole list. We looked for the obvious peptides on Willow's own site and there is no page for any of them — sermorelin, CJC-1295, ipamorelin, tesamorelin and MK-677 are not sold here, and neither is glutathione, standalone B-12, methylene blue, BPC-157, TB-500, testosterone or any supplement.

So Willow is on this site as an adjacent NAD+ and GLP-1 option and nothing more. It is not on our sermorelin ranking and it never will be while that list holds, because answering "I want a growth-hormone peptide" with a weight-loss service is a product swap, not an alternative. If you want to know what actually separates the two categories, what sermorelin costs per month covers the peptide side and our GLP-1 page covers the other.

The $199, and the two things attached to it

NAD+, injectable, subcutaneous, 50 mg — $199. Dispensed by a named pharmacy, which Willow states in its terms.

Two qualifiers travel with that number and both are the company's own words, not our inference.

First, it is billed against a 28-day supply. The checkout says you receive a 28-day supply every month. Twenty-eight-day cycles mean thirteen fills a year, not twelve — so a year of NAD+ at $199 is about $2,587, not the $2,388 that a "/mo" figure implies. That is roughly one extra charge a year, and it is the single most common way a genuinely flat price still costs more than you budgeted.

Second, $199 is the price at 50 mg. Willow's FAQ says medication costs vary by dosage, and its terms say the fee may be increased by a dosage increase. So it is a flat rate at a dose, not a flat rate forever.

Its weight-loss line is priced separately and conventionally: compounded semaglutide $299 a month and tirzepatide $399, the same either way whether you take the injection or the sublingual tablet, with an anti-nausea add-on at $30.

The value story nobody advertises

Here is a detail worth more than the headline. Willow's NAD+ protocol runs three injections a week in the first month, then optionally drops to once a week afterwards. The price does not change when the frequency drops.

That is not a scandal and it is not hidden — it is simply the arithmetic nobody puts in a comparison table. From month two you are paying the same $199 for roughly a third of the injections. Whether that is fine depends on what the maintenance dose actually is, which the company does not publish, and it is the first question to ask at intake, not after the second charge.

An additive, or a treatment?

Willow's public NAD+ page sells the product on cognition, energy and brain fog, standalone. Its own internal product copy describes the same product as "an NAD+ additive… during your GLP-1 treatment".

The funnel matches the second description more than the first: the NAD+ intake is a weight-loss questionnaire, asking BMI, GLP-1 history and diabetes status. To Willow's credit, it does not gate on the answers: a healthy-weight applicant with no weight-loss goal reaches the same $199 checkout, so the product really is available on its own. But the shape of the thing tells you where it came from, and it is worth knowing that the company that sells it internally thinks of it as an accessory to a weight-loss program.

Worth saying plainly for readers of this site: NAD+ is not a growth-hormone peptide and has no relationship to the sleep-architecture mechanism sermorelin works through. Nothing about a GHRH analog's effect on slow-wave sleep transfers to it.

What Willow is unusually good at

Credit where it is earned. On disclosure Willow is at the top of the services this site covers, not the bottom:

• •Twenty-five-plus named physicians, each with their own bio page, under a named chief medical officer who is dual board-certified. No other service we have reviewed names that many practicing doctors — Found Health names more senior advisers, and at Sesame Care you choose the individual clinician yourself, but neither publishes a bench like this. (No NPIs are published, so we have not verified any of them individually.)
• •Three dispensing pharmacies named in its terms — Red Rock Home Pharmacy (which dispenses the NAD+), Epiq Pharmacy and The Pharmacy Hub — rather than the usual "licensed US pharmacies". One caveat worth carrying: The Pharmacy Hub is the same dispensary, at the same Miami address, that Try Ageless and System Labs name in our sermorelin ranking. Three unrelated brands, one facility — so a named pharmacy tells you the supply chain is visible, not that it is independent.
• •A real answer on states: Willow serves 36 and does not serve 14. Its sign-up form still lets you pick any of the fifty, so check the list, not the dropdown.
• •No FDA warning letter on record. As of August 2026, nothing against Willow, either of its legal entities, or any of the three pharmacies it names¹ — how we check.

The rest of the caveats

The medication is compounded and not FDA-approved, which Willow says itself. Cancellation requests must arrive two full calendar days before the next ship date. It is explicitly a women's brand — its terms frame the whole service around women's health services — even though the NAD+ page itself is gender-neutral. Its "4.9 out of 5 from 2,200-plus reviews" and "100,000-plus patients" claims sit on no third-party platform we could find. And the NAD+ page is in the site's own navigation but absent from its sitemap, which is a small thing that tends to mean a page nobody owns.

On the GLP-1 side, the evidence behind the molecules is genuinely strong — semaglutide and tirzepatide both have large randomized weight-loss trials behind them²³ — but those trials were run on the branded products, not on compounded copies, and that distinction is the whole of the compounded-GLP-1 question.

Bottom line

$199 a month for a 50 mg NAD+ injection, and it really is the month-to-month rate — no prepay tier, no teaser month, which after checking dozens of these is unusual. Set against it: billing runs on 28-day cycles, so a year is thirteen charges and about $2,587; the dose frequency drops after month one and the price does not; the company's own internal copy treats the product as a GLP-1 add-on; and it sells no sermorelin and no GH peptide at all, so for a reader of this site it is an adjacent option, not a peptide one. What it does better than almost anyone: it names its doctors, names its pharmacies, and publishes a real state list.